AbbVie Inc Says Adjusted Non-GAAP Earnings For Q1 Of 2024 Are Expected To Include Acquired IPR&D And Milestones Expense Of $164M On A Pre-Tax Basis; 2024 Adj Diluted EPS Guidance Range, Including Impact Of First Quarter 2024 Acquired IPR&D And Mil...

AbbVie, Inc. +1.06%

AbbVie, Inc.

ABBV

166.41

+1.06%

- SEC Filing

Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via